An AI-native biotechnology company designing oral peptide therapeutics from non-canonical amino acids for immune disease, spun out of Caltech.
Aizen Therapeutics / Caltech
Released November 21, 2024
De novo peptide design across non-canonical amino acid space, using guided diffusion over receptor-ligand interfaces to reach D-amino acid chemistry.